nonsmall

• “Woburn, Mass., biotechnology company ArQule soared 2.22, or 63%, to 5.72, after its anticancer treatment candidate, in combination with another drug, showed a two-thirds improvement in progression-free survival for patients with advanced nonsmall-cell lung cancer.”

  The Wall Street Journal: Gulf Island, Seahawk Gain on Drilling News as Small Caps Fall

• “Bayer estimates that 1.4 million people world-wide are diagnosed with lung cancer every year, and about 160,000 in the U.S. and 342,000 in Europe die from nonsmall-cell lung cancer annually.”

  The Wall Street Journal: Bayer Cancer Drug Fails to Meet Primary Goal

• “Inc., the oral drug did reach its secondary goal of so-called progression-free survival where the disease didn't get worse in patients with nonsquamous, nonsmall-cell lung cancer, Bayer said.”

  The Wall Street Journal: Bayer Cancer Drug Fails to Meet Primary Goal

• “Abbott Laboratories to develop a diagnostic test to screen patients with nonsmall-cell lung cancer for the presence of alterations in the ALK gene.”

  The Wall Street Journal: New Pfizer Drug Shrinks Some Lung-Cancer Tumors

• “OSI Pharmaceuticals rose 8.3% after a Phase III study of Tarceva showed improvement in survival when used after initial chemotherapy in patients with advanced nonsmall cell lung cancer.”

  The Wall Street Journal: Dow Climbs 2.3% in Broad Rally

• “Another drug in Amgen's pipeline, motesanib, suffered a setback in November, when a trial was suspended because of higher death rates in late-stage nonsmall-cell lung-cancer patients.”

  The Wall Street Journal: Amgen's Net Profit Increases 15%

• “AstraZeneca said a Phase II study of the use of Recentin in nonsmall-cell lung cancer won't progress into Phase III after failing to meet its main goal.”

  The Wall Street Journal: AstraZeneca Ends

• “Nonetheless, this together with the approvals in nonsmall-cell lung, breast-cancer and renal-cell carcinoma should ensure continued strong growth of Avastin in markets outside the U.S. and Japan, which we forecast at 3.6 billion Swiss francs by 2012," he said.”

  The Wall Street Journal: Roche's Avastin Cleared

• “The Sunnyvale, Calif., pharmaceutical company received a so-called nonapprovable letter from the FDA for Xcytrin injection in patients with nonsmall-cell lung cancer with brain metastases.”

  The Wall Street Journal: Lindsay, Mobile Mini Post Gains

• “Sales of the drug, approved for colorectal cancer and nonsmall-cell lung cancer, have increased as doctors have begun to use it as an off-label treatment for other cancer types.”

  The Wall Street Journal: Genentech's Avastin

Show 10 more examples...